Loading…
Loading…
We're curious about the VESALIUS-CV results and how you expect them to impact the overall market opportunity for Repatha?
Can you provide some color on the time line to file for approval, especially with regards to the results for -- from FORTITUDE-102, do you need those for filing?
Can you help us understand what to expect on the Bemarituzumab Phase III study readout coming up here in the second quarter?
Could you describe the key lessons you expect to learn from the Repatha VESALIUS-CV outcome study results, how you can leverage those lessons across your portfolio